Compare Berkshire Hathaway Inc Class B (BRK.B) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Berkshire Hathaway Inc Class B vs Medpace Holdings Inc — how do they compare? Berkshire Hathaway Inc Class B trades at $491.26, while Medpace Holdings Inc trades at $536.29 (market cap $15.31B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, Berkshire Hathaway Inc Class B nearer its low. Which is the better fit depends on your goals.
| BRK.B | MEDP | |
|---|---|---|
Sector | Financials | Technology |
52-Week High | $513.70 | $620.59 |
52-Week Low | $459.10 | $308.88 |
Market Cap | — | $15.31B |
Enterprise Value | — | $14.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BRK.B trades at $496.79, up 0.63% today, with a bullish technical outlook supported by moving averages and key support at $494. Analyst consensus is positive with 57% buy ratings, though fundamental data is currently unavailable for detailed valuation metrics. The stock shows neutral momentum oscillators but strong trend strength per ADX.
The outlook remains favorable given strong analyst support and institutional confidence, but investors face risks from macroeconomic sensitivity and execution challenges in Berkshire Hathaway's diverse portfolio. Upside is contingent on earnings growth and market stability.
MEDP trades at $530.19, down 1.49% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected on July 22, 2026. Fundamentals show robust profitability with a 17.19% net income margin and 77.25% ROE, though valuation ratios like P/E of 33.74 are elevated. Recent news highlights volatility and a class action lawsuit filed in June 2026.
Outlook is mixed; earnings momentum and high profitability support upside, but high valuation and legal overhang pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term gains. Investors should weigh strong operational performance against valuation concerns and litigation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
